Allergy Delabeling in Antibiotic Stewardship - Evaluations

Enrolling by invitation

Conditions studied: Beta Lactam Allergy in Patients With a Hematologic Malignancy

In brief

The goal of this RENEW-EVAL project is to understand the potential barriers to implementation of the RENEW intervention into the routine clinical care of patients with a hematological malignancy.

Key facts

Study ID

NCT06967467

Run by

Abramson Cancer Center at Penn Medicine

People needed

80

Starts

2025-12-01

Expected to finish

2029-10-01

Last updated by the study team

2026-06-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient participants:
• a diagnosis of a hematologic malignancy (lymphoma, leukemia, myeloma)
• a prior label applied to their medical record to indicate a beta lactam allergy
• hospitalized as an inpatient to an oncology service at the time the study is conducted
• Clinician participants:
• member of the primary inpatient care team

You may not qualify if…

• Patient participants:
• meet one of the exclusionary criteria for the RENEW clinical intervention
• Clinician participants:
• no exclusions

Where it is running

• Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.